• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    GCC Point of Care Molecular Diagnostics Market

    ID: MRFR/MED/50174-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    GCC Point of Care Molecular Diagnostics Market Research Report By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Application (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End Use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics) and By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology)-Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    GCC Point of Care Molecular Diagnostics Market Research Report-Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    GCC Point of Care Molecular Diagnostics Market Summary

    The GCC Point of Care Molecular Diagnostics market is projected to grow significantly from 156.2 USD Million in 2024 to 468.8 USD Million by 2035.

    Key Market Trends & Highlights

    GCC Point of Care Molecular Diagnostics Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 10.5 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 468.8 USD Million, indicating robust growth potential.
    • In 2024, the market is valued at 156.2 USD Million, reflecting the increasing demand for rapid diagnostic solutions.
    • Growing adoption of point of care testing due to the need for timely and accurate diagnostics is a major market driver.

    Market Size & Forecast

    2024 Market Size 156.2 (USD Million)
    2035 Market Size 468.8 (USD Million)
    CAGR (2025-2035) 10.5%

    Major Players

    LumiraDx, Qiagen, Mayo Clinic Laboratories, Roche, Molecular Testing Labs, Hologic, bioMérieux, Ortho Clinical Diagnostics, Luminex, Cepheid, Abbott, Siemens Healthineers, BD, Thermo Fisher Scientific, GenMark Diagnostics

    GCC Point of Care Molecular Diagnostics Market Trends

    The GCC Point of Care Molecular Diagnostics Market is experiencing significant growth driven by several key factors. One of the primary market drivers is the increasing demand for rapid diagnostic solutions, particularly amidst health crises like pandemics. The need for quick and accurate testing is underscored by the GCC governments' focus on enhancing healthcare systems to provide immediate responses to contagious diseases. Countries within the region, such as the UAE and Saudi Arabia, are investing heavily in healthcare infrastructure, making the adoption of point-of-care molecular diagnostics more feasible.

    There are substantial opportunities in the GCC market that can be explored, particularly in rural and underserved areas where access to large healthcare facilities is limited.This gap can be filled by mobile and portable diagnostics, allowing healthcare providers to deliver timely care. The support from the government in terms of funding and initiatives aimed at improving healthcare accessibility can further enhance the expansion of point-of-care testing solutions. Recent trends within the GCC market reflect a growing inclination towards telemedicine and remote patient monitoring, which complements the use of molecular diagnostics.

    The integration of advanced technologies, such as artificial intelligence and machine learning, into point-of-care devices is enhancing their efficiency and accuracy. Furthermore, regulatory bodies in the GCC are increasingly streamlining approval processes for new diagnostic products, which encourages innovation and the introduction of new technologies.As these elements come together, the GCC is poised to become a leading region in the adoption of point-of-care molecular diagnostics, significantly impacting healthcare delivery.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    GCC Point of Care Molecular Diagnostics Market Drivers

    Market Segment Insights

    GCC Point of Care Molecular Diagnostics Market Segment Insights

    GCC Point of Care Molecular Diagnostics Market Segment Insights

    Point of Care Molecular Diagnostics Market Product Type Insights

    Point of Care Molecular Diagnostics Market Product Type Insights

    The GCC Point of Care Molecular Diagnostics Market showcases a diverse range of product types, each playing a critical role in the landscape of medical diagnostics within the region. Among the prominent categories is PCR Tests, which are essential for detecting specific genetic material, offering quick results that support timely clinical decision-making. These tests have become integral for managing infectious diseases, especially in the context of outbreaks, as they can be deployed rapidly at point-of-care settings. Nucleic Acid Amplification Tests stand out for their ability to enhance sensitivity and specificity, making them pivotal for the detection of low viral loads.

    This segment is evolving significantly alongside trends in precision medicine and personalized healthcare. Microarray technology is another notable contributor, enabling simultaneous analysis of multiple targets, which streamlines testing processes and enhances the understanding of complex disease mechanisms. This multiparameter approach is particularly beneficial in the GCC, as it aligns with healthcare initiatives aimed at advancing genomics research. Next-Generation Sequencing (NGS) is quickly gaining traction in the market due to its capability to generate large volumes of data, thereby facilitating comprehensive genomic analysis.

    This technology not only enhances disease diagnosis but also aids in researching therapeutic targets, driving the growth of tailored treatments.Other Genetic Tests also hold a crucial position in the GCC Point of Care Molecular Diagnostics Market, catering to a variety of applications such as cancer diagnostics, rare genetic disorders, and pharmacogenomics. The increasing prevalence of chronic diseases, coupled with the region's preference for rapid diagnostics, fuels the demand for these advanced tests.

    Overall, the product types within this market are well-positioned to address the rising healthcare demands in the GCC, supported by government initiatives to bolster healthcare infrastructure and patient accessibility. The market is trending towards more innovative solutions that improve diagnostic accuracy and patient outcomes, reflecting the overarching goals of the GCC healthcare strategy to enhance disease management and establish a robust healthcare system.

    Point of Care Molecular Diagnostics Market Application Insights

    Point of Care Molecular Diagnostics Market Application Insights

    The GCC Point of Care Molecular Diagnostics Market showcases a diverse landscape within its Application domain, with significant focus on various pivotal areas. Infectious disease diagnostics have gained prominence due to the increasing prevalence of viral and bacterial infections, necessitating rapid and accurate testing solutions. Genetic testing plays a crucial role in personalized medicine, allowing healthcare providers to tailor treatments based on individual genetic profiles, thus paving the way for improved patient outcomes.

    Cancer diagnosis within this market segment is vital, especially with the rising cancer rates in the GCC region, prompting innovations in early detection methods to enhance survival rates.Metabolic disorders are also increasingly recognized, given their implications on public health and the demand for effective screening tools. The growth in these applications is fueled by government initiatives aimed at enhancing healthcare infrastructure and the growing awareness of preventative health measures among residents.

    As a consequence, the demand for advanced molecular diagnostics in these areas is set to expand significantly, driven by the need for timely and precise healthcare solutions in the GCC region.

    Point of Care Molecular Diagnostics Market End Use Insights

    Point of Care Molecular Diagnostics Market End Use Insights

    The End Use segment of the GCC Point of Care Molecular Diagnostics Market holds substantial significance in enhancing healthcare delivery across the region. Hospitals play a pivotal role by integrating Point of Care Molecular Diagnostics into critical care and emergency services, ensuring rapid diagnosis and treatment. Diagnostic Laboratories complement this by focusing on efficiency and accuracy, which are essential for the growing demand for reliable test results.

    Home Care Settings are increasingly recognized for their convenience, allowing patients to receive timely diagnostics without the need for hospital visits, which has become particularly important in light of recent healthcare trends.Outpatient Clinics represent another vital aspect, providing accessible diagnostic services that alleviate pressure on hospital systems while serving a diverse population. The focus on improving patient outcomes, minimizing waiting times for results, and enhancing overall healthcare quality drives the growth of these segments.

    As the GCC region continues to invest in healthcare infrastructure, the importance of each segment in the GCC Point of Care Molecular Diagnostics Market is expected to expand, reflecting a commitment to advanced and responsive healthcare solutions.The collaboration between these various End Use categories contributes to a more effective health system by providing comprehensive diagnostic capabilities tailored to the diverse needs of patients in the GCC.

    Point of Care Molecular Diagnostics Market Technology Insights

    Point of Care Molecular Diagnostics Market Technology Insights

    The Technology segment of the GCC Point of Care Molecular Diagnostics Market is marked by significant advancements and innovations that cater to the rising demand for efficient and rapid diagnostic solutions. Key technologies such as Isothermal Amplification and Polymerase Chain Reaction (PCR) are at the forefront of this market, widely praised for their ability to deliver accurate results in a short timeframe, which is crucial for timely treatment decisions. Meanwhile, Sanger Sequencing remains an important method for genetic testing, providing reliable data for various applications in healthcare.

    Additionally, CRISPR Technology is gaining traction due to its potential for precise gene editing and rapid diagnostics, thus revolutionizing the way genetic diseases are treated. The continuous evolution of these technologies is driven by increasing investments in Research and Development, as well as supportive government policies in the GCC region aimed at enhancing healthcare infrastructure.

    This growth in technology not only accelerates the pace of diagnosis but also enhances patient care outcomes, making it a dominant force in the overall market landscape.As the demand for personalized medicine rises, the importance of sophisticated and efficient molecular diagnostics technologies becomes even more critical in addressing healthcare challenges faced in the GCC.

    Get more detailed insights about GCC Point of Care Molecular Diagnostics Market Research Report-Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The GCC Point of Care Molecular Diagnostics Market has been witnessing significant growth, characterized by advancements in technology and an increasing demand for rapid diagnostic solutions. The competitive landscape is shaped by a mix of established players and emerging companies striving to gain market share through innovation and enhancing product offerings. This market is driven by the need for timely and accurate diagnostics, particularly in the face of public health challenges and the growing prevalence of infectious diseases in the region.

    The integration of molecular diagnostics into point-of-care settings enables healthcare providers to deliver immediate results, ultimately improving patient outcomes and operational efficiency. As a result, companies are increasingly focusing on the development of user-friendly, portable devices that can be deployed in various healthcare environments.LumiraDx has made notable strides in the GCC Point of Care Molecular Diagnostics Market with its innovative diagnostic platforms that cater specifically to the region's healthcare needs. The company's strength lies in its focus on delivering rapid and accurate testing solutions, particularly for infectious diseases and chronic conditions.

    With a strong emphasis on technological advancements, LumiraDx has established a solid presence in the GCC, offering products that enable healthcare professionals to quickly interpret results at the point of care. The robustness of its product lineup, combined with a commitment to enhanced patient care, allows LumiraDx to maintain a competitive edge in a rapidly evolving market.

    Additionally, the company is actively engaged in expanding its distribution networks and fostering partnerships within the region, which further solidifies its position amidst market competition.Qiagen holds a prominent place in the GCC Point of Care Molecular Diagnostics Market, driven by its comprehensive portfolio of molecular diagnostic solutions and a strong reputation for quality and reliability. The company offers a wide range of products and services tailored to meet the diverse needs of healthcare providers, including rapid testing kits that facilitate the quick detection of pathogens and genetic conditions.

    Qiagen's strengths in the GCC region are further enhanced by strategic mergers and acquisitions that have broadened its capabilities and market reach, allowing it to leverage synergies to enhance its product offerings. The company continues to invest in research and development to innovate its existing technology and create new solutions that resonate with the needs of healthcare stakeholders. Overall, Qiagen’s established brand presence, commitment to quality, and focus on customer satisfaction position it favorably within the competitive landscape of the GCC Point of Care Molecular Diagnostics Market.

    Key Companies in the GCC Point of Care Molecular Diagnostics Market market include

    Industry Developments

    The GCC Point of Care Molecular Diagnostics Market has been experiencing significant developments recently. Companies like LumiraDx and Roche have expanded their product offerings to enhance the speed and accuracy of diagnostic results, responding to the increased demand for rapid testing, especially amidst ongoing health crises. The market has also seen promising growth in valuation, with key players such as Thermo Fisher Scientific and Abbott driving advancements in testing technologies. Notably, in August 2023, Hologic announced a partnership with local healthcare providers to improve access to molecular testing across the GCC region, which is expected to further catalyze market growth.

    On the merger front, Qiagen announced the acquisition of a regional diagnostic firm in January 2023, aligning with its strategy to strengthen its presence in the GCC. Additionally, the consolidation of resources and expertise among key players, like Siemens Healthineers and BD, is expected to enhance the market's capabilities and drive innovation. In the past few years, the region has witnessed a push for localized manufacturing of diagnostic devices, aiding in timely responses to public health needs and bolstering self-sufficiency in diagnostics.

    Market Segmentation

    Outlook

    • Isothermal Amplification
    • Polymerase Chain Reaction
    • Sanger Sequencing
    • CRISPR Technology

    Report Scope

     
    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 144.25(USD Million)
    MARKET SIZE 2024 156.25(USD Million)
    MARKET SIZE 2035 468.75(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 10.503% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED LumiraDx, Qiagen, Mayo Clinic Laboratories, Roche, Molecular Testing Labs, Hologic, bioMérieux, Ortho Clinical Diagnostics, Luminex, Cepheid, Abbott, Siemens Healthineers, BD, Thermo Fisher Scientific, GenMark Diagnostics
    SEGMENTS COVERED Product Type, Application, End Use, Technology
    KEY MARKET OPPORTUNITIES Rapid technological advancements, Increasing prevalence of infectious diseases, Growing demand for personalized medicine, Expansion of healthcare infrastructure, Rising investment in diagnostics R&D
    KEY MARKET DYNAMICS increased demand for rapid testing, technological advancements in diagnostics, rising prevalence of infectious diseases, growing public health awareness, investments in healthcare infrastructure
    COUNTRIES COVERED GCC

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the GCC Point of Care Molecular Diagnostics Market in 2024?

    The GCC Point of Care Molecular Diagnostics Market is expected to be valued at 156.25 million USD in 2024.

    What is the projected market size for the GCC Point of Care Molecular Diagnostics Market by 2035?

    By 2035, the GCC Point of Care Molecular Diagnostics Market is projected to grow to 468.75 million USD.

    What is the expected CAGR for the GCC Point of Care Molecular Diagnostics Market from 2025 to 2035?

    The expected CAGR for the market from 2025 to 2035 is 10.503%.

    Which product segment holds the largest market share in the GCC Point of Care Molecular Diagnostics Market?

    The PCR Tests segment is expected to dominate the market, valued at 45.0 million USD in 2024 and projected to reach 135.0 million USD by 2035.

    What are the key players involved in the GCC Point of Care Molecular Diagnostics Market?

    Key players in the market include LumiraDx, Qiagen, Mayo Clinic Laboratories, Roche, and Abbott among others.

    What is the market value of Nucleic Acid Amplification Tests in 2024?

    Nucleic Acid Amplification Tests are valued at 35.0 million USD in 2024.

    What opportunities are expected to drive the growth of the GCC Point of Care Molecular Diagnostics Market?

    The growth is driven by technological advancements and the rising demand for rapid diagnostics.

    How is the Microarray segment expected to perform in the market by 2035?

    The Microarray segment is anticipated to grow from 30.0 million USD in 2024 to 90.0 million USD by 2035.

    How will the Next-Generation Sequencing segment contribute to the market size in the future?

    Next-Generation Sequencing is projected to grow from 25.0 million USD in 2024 to 75.0 million USD by 2035.

    What challenges might affect the GCC Point of Care Molecular Diagnostics Market in the coming years?

    Challenges may include regulatory hurdles and market competition impacting pricing strategies.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. GCC
    59. Point of Care Molecular Diagnostics Market, BY Product Type (USD Million)
    60. PCR
    61. Tests
    62. Nucleic Acid Amplification Tests
    63. Microarray
    64. Next-Generation
    65. Sequencing
    66. Other Genetic Tests
    67. GCC
    68. Point of Care Molecular Diagnostics Market, BY Application (USD Million)
    69. Infectious
    70. Diseases
    71. Genetic Testing
    72. Cancer
    73. Diagnosis
    74. Metabolic Disorders
    75. GCC
    76. Point of Care Molecular Diagnostics Market, BY End Use (USD Million)
    77. Hospitals
    78. Diagnostic
    79. Laboratories
    80. Home Care Settings
    81. Outpatient
    82. Clinics
    83. GCC Point of Care Molecular
    84. Diagnostics Market, BY Technology (USD Million)
    85. Isothermal
    86. Amplification
    87. Polymerase Chain Reaction
    88. Sanger
    89. Sequencing
    90. CRISPR Technology
    91. Competitive Landscape
    92. Overview
    93. Competitive
    94. Analysis
    95. Market share Analysis
    96. Major
    97. Growth Strategy in the Point of Care Molecular Diagnostics Market
    98. Competitive
    99. Benchmarking
    100. Leading Players in Terms of Number of Developments
    101. in the Point of Care Molecular Diagnostics Market
    102. Key
    103. developments and growth strategies
    104. New Product Launch/Service
    105. Deployment
    106. Merger & Acquisitions
    107. Joint
    108. Ventures
    109. Major Players Financial Matrix
    110. Sales
    111. and Operating Income
    112. Major Players R&D Expenditure.
    113. Company
    114. Profiles
    115. LumiraDx
    116. Financial
    117. Overview
    118. Products Offered
    119. Key
    120. Developments
    121. SWOT Analysis
    122. Key
    123. Strategies
    124. Qiagen
    125. Financial
    126. Overview
    127. Products Offered
    128. Key
    129. Developments
    130. SWOT Analysis
    131. Key
    132. Strategies
    133. Mayo Clinic Laboratories
    134. Financial
    135. Overview
    136. Products Offered
    137. Key
    138. Developments
    139. SWOT Analysis
    140. Key
    141. Strategies
    142. Roche
    143. Financial
    144. Overview
    145. Products Offered
    146. Key
    147. Developments
    148. SWOT Analysis
    149. Key
    150. Strategies
    151. Molecular Testing Labs
    152. Financial
    153. Overview
    154. Products Offered
    155. Key
    156. Developments
    157. SWOT Analysis
    158. Key
    159. Strategies
    160. Hologic
    161. Financial
    162. Overview
    163. Products Offered
    164. Key
    165. Developments
    166. SWOT Analysis
    167. Key
    168. Strategies
    169. bioMérieux
    170. Financial
    171. Overview
    172. Products Offered
    173. Key
    174. Developments
    175. SWOT Analysis
    176. Key
    177. Strategies
    178. Ortho Clinical Diagnostics
    179. Financial
    180. Overview
    181. Products Offered
    182. Key
    183. Developments
    184. SWOT Analysis
    185. Key
    186. Strategies
    187. Luminex
    188. Financial
    189. Overview
    190. Products Offered
    191. Key
    192. Developments
    193. SWOT Analysis
    194. Key
    195. Strategies
    196. Cepheid
    197. Financial
    198. Overview
    199. Products Offered
    200. Key
    201. Developments
    202. SWOT Analysis
    203. Key
    204. Strategies
    205. Abbott
    206. Financial
    207. Overview
    208. Products Offered
    209. Key
    210. Developments
    211. SWOT Analysis
    212. Key
    213. Strategies
    214. Siemens Healthineers
    215. Financial
    216. Overview
    217. Products Offered
    218. Key
    219. Developments
    220. SWOT Analysis
    221. Key
    222. Strategies
    223. BD
    224. Financial
    225. Overview
    226. Products Offered
    227. Key
    228. Developments
    229. SWOT Analysis
    230. Key
    231. Strategies
    232. Thermo Fisher Scientific
    233. Financial
    234. Overview
    235. Products Offered
    236. Key
    237. Developments
    238. SWOT Analysis
    239. Key
    240. Strategies
    241. GenMark Diagnostics
    242. Financial
    243. Overview
    244. Products Offered
    245. Key
    246. Developments
    247. SWOT Analysis
    248. Key
    249. Strategies
    250. References
    251. Related
    252. Reports
    253. LIST
    254. OF ASSUMPTIONS
    255. GCC Point of Care Molecular Diagnostics
    256. Market SIZE ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD Billions)
    257. GCC
    258. Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY APPLICATION,
    259. 2035 (USD Billions)
    260. GCC Point of Care Molecular
    261. Diagnostics Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    262. GCC
    263. Point of Care Molecular Diagnostics Market SIZE ESTIMATES & FORECAST, BY TECHNOLOGY,
    264. 2035 (USD Billions)
    265. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    266. ACQUISITION/PARTNERSHIP
    267. LIST
    268. Of figures
    269. MARKET SYNOPSIS
    270. GCC
    271. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY PRODUCT TYPE
    272. GCC
    273. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY APPLICATION
    274. GCC
    275. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY END USE
    276. GCC
    277. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGY
    278. KEY
    279. BUYING CRITERIA OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    280. RESEARCH
    281. PROCESS OF MRFR
    282. DRO ANALYSIS OF POINT OF CARE MOLECULAR
    283. DIAGNOSTICS MARKET
    284. DRIVERS IMPACT ANALYSIS: POINT OF
    285. CARE MOLECULAR DIAGNOSTICS MARKET
    286. RESTRAINTS IMPACT ANALYSIS:
    287. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    288. SUPPLY / VALUE
    289. CHAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
    290. POINT
    291. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2025 (% SHARE)
    292. POINT
    293. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019 TO 2035 (USD Billions)
    294. POINT
    295. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 (% SHARE)
    296. POINT
    297. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    298. POINT
    299. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USE, 2025 (% SHARE)
    300. POINT
    301. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    302. POINT
    303. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 (% SHARE)
    304. POINT
    305. OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 TO 2035 (USD Billions)
    306. BENCHMARKING
    307. OF MAJOR COMPETITORS

    GCC Point of Care Molecular Diagnostics Market Segmentation

    • Point of Care Molecular Diagnostics Market By Product Type (USD Million, 2019-2035)

      • PCR Tests
      • Nucleic Acid Amplification Tests
      • Microarray
      • Next-Generation Sequencing
      • Other Genetic Tests

     

    • Point of Care Molecular Diagnostics Market By Application (USD Million, 2019-2035)

      • Infectious Diseases
      • Genetic Testing
      • Cancer Diagnosis
      • Metabolic Disorders

     

    • Point of Care Molecular Diagnostics Market By End Use (USD Million, 2019-2035)

      • Hospitals
      • Diagnostic Laboratories
      • Home Care Settings
      • Outpatient Clinics

     

    • Point of Care Molecular Diagnostics Market By Technology (USD Million, 2019-2035)

      • Isothermal Amplification
      • Polymerase Chain Reaction
      • Sanger Sequencing
      • CRISPR Technology
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027